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Abstract
Background: Latin America, China and India are experiencing unprecedentedly rapid demographic ageing with an
increasing number of people with dementia. The 10/66 Dementia Research Group's title refers to the 66% of people with
dementia that live in developing countries and the less than one tenth of population-based research carried out in those
settings. This paper describes the protocols for the 10/66 population-based and intervention studies that aim to redress
this imbalance.
Methods/design: Cross-sectional comprehensive one phase surveys have been conducted of all residents aged 65 and
over of geographically defined catchment areas in ten low and middle income countries (India, China, Nigeria, Cuba,
Dominican Republic, Brazil, Venezuela, Mexico, Peru and Argentina), with a sample size of between 1000 and 3000
(generally 2000). Each of the studies uses the same core minimum data set with cross-culturally validated assessments
(dementia diagnosis and subtypes, mental disorders, physical health, anthropometry, demographics, extensive non
communicable disease risk factor questionnaires, disability/functioning, health service utilisation, care arrangements and
caregiver strain). Nested within the population based studies is a randomised controlled trial of a caregiver intervention
for people with dementia and their families (ISRCTN41039907; ISRCTN41062011; ISRCTN95135433;
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ISRCTN66355402; ISRCTN93378627; ISRCTN94921815). A follow up of 2.5 to 3.5 years will be conducted in 7
countries (China, Cuba, Dominican Republic, Venezuela, Mexico, Peru and Argentina) to assess risk factors for incident
dementia, stroke and all cause and cause-specific mortality; verbal autopsy will be used to identify causes of death.
Discussion: The 10/66 DRG baseline population-based studies are nearly complete. The incidence phase will be
completed in 2009. All investigators are committed to establish an anonymised file sharing archive with monitored public
access. Our aim is to create an evidence base to empower advocacy, raise awareness about dementia, and ensure that
the health and social care needs of older people are anticipated and met.
Background
The 10/66 dementia research group
The title of the 10/66 Dementia Research Group [1-4]
refers to the 66% of people with dementia that live in
developing countries and the less than one tenth of pop-
ulation-based research carried out in those settings. We
have attempted to redress the research imbalance through
south-south and south-north research collaborations.
Our first symposium in Cochin in 1998 established clear
priorities [1], which have guided our subsequent research
programme.
1) Methodological problems needed first to be
addressed, particularly development of culture- and -edu-
cation fair dementia diagnostic procedures, a prerequisite
for meaningful comparison between regions [2]. Our
pilot studies in 26 centres in Latin America and the Carib-
bean, Africa, India, Russia, China and SE Asia demon-
strated the feasibility and validity of a one stage culture
and education-fair diagnostic protocol for population-
based research [5,6], the resulting '10/66 Dementia' out-
come being derived from a probabilistic algorithm.
2) More research was needed to describe dementia prev-
alence and incidence. Local evidence of numbers of peo-
ple affected, and associated burden would raise awareness
and inform policymaking. Regional variations in disease
frequency could give clues regarding aetiology, if obtained
using harmonised and cross-culturally valid methods.
3) Description of care arrangements for people with
dementia. In our pilot studies we showed that levels of
caregiver strain, among caregivers of people with demen-
tia are at least as high as those typically reported from
developed countries, despite the strong traditions of
extended family care in most of the countries studied [7-
9]. We have also highlighted the lack of awareness and
understanding of the nature of the dementia syndrome,
and the unresponsiveness of health care services as cur-
rently constituted [8,10,11]. Behavioural symptoms, such
as agitation, wandering, calling out repeatedly, are com-
mon in developing countries, associated with stigma and
blame, and an important source of distress for caregivers
[12].
4) The effectiveness of new services for people with
dementia and their caregivers. We have shown that com-
munity health workers in Brazil [13] and India [14] can,
after one day of training, identify cases of dementia in the
community with reasonable accuracy using their knowl-
edge of older people from their outreach work (which
focuses mainly on maternal and child health). We have
gone on to develop a simple five session caregiver educa-
tion and training intervention, suitable for administration
by a community health worker.
Since the pilot phase (1999–2001), the 10/66 DRG has
conducted population-based surveys of dementia preva-
lence and impact in 14 catchment areas in 10 low and
middle income countries (2003–2007). Nested within the
population-based studies is a randomized controlled trial
of a caregiver intervention for people with dementia and
their families. We will shortly embark on an incidence
phase with a 2.5 to three year follow-up of baseline partic-
ipants in seven of the 10 countries (2007–2010). The pur-
pose of this paper is to describe the protocols for the three
elements of the research programme; the baseline survey,
the incidence phase, the casefinder approach and the ran-
domized controlled trial; and in doing so, publicize the
publicly accessible 10/66 data archive that will be estab-
lished by the following centres: India (Vellore and Chen-
nai), Nigeria, China, Cuba, the Dominican Republic,
Venezuela, Mexico, Peru and Argentina. The Brazilian cen-
tre will establish an independent data archive.
The demographic and health transitions
Demographic ageing proceeds apace in all world regions,
more rapidly than first anticipated [15]. The proportion of
older people increases as mortality falls and life expect-
ancy increases. Population growth slows as fertility
declines to replacement levels. Latin America, China and
India are experiencing unprecedentedly rapid demo-
graphic ageing (Figures 1 and 2).
In the accompanying health transition non-communica-
ble diseases (NCD) assume a progressively greater signifi-
cance in low and middle income countries (LAMIC).
NCDs are already the leading cause of death in all world
regions apart from sub-Saharan Africa. Of the 35 million
deaths in 2005 from NCDs, 80% will have been in LAMICBMC Public Health 2007, 7:165 http://www.biomedcentral.com/1471-2458/7/165
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[16]. This is partly because most of the world's older peo-
ple live in these regions – 60% now rising to 80% by
2050. However, changing patterns of risk exposure also
contribute. Latin America exemplifies the third stage of
health transition. As life expectancy improves, and high
fat diets, cigarette smoking and sedentary lifestyles
become more common, so CVDs have maximum public
health salience – more so than in stage 2 regions (China
and India) where risk exposure is not yet so elevated, and
in stage 4 regions (Europe) where public health measures
reduced exposure levels [17]. The INTERHEART cross-
national case-control study suggests that risk factors for
myocardial infarction operate equivalently in all world
regions, including Latin America and China [18].
Dementia in developing countries
Global burden
It has been recently estimated that 24.2 million people
live with dementia worldwide (based upon systematic
review of prevalence data and expert consensus), with 4.6
million new cases annually [19] (similar to the annual
global incidence of non-fatal stroke [20]). Most people
with dementia live in LAMIC, 60% in 2001 rising to 71%
by 2040. Numbers will double every twenty years to over
80 millions by 2040. Increases to 2040 will be much
sharper in developing (300%) than developed regions
(100%). Growth in Latin America will exceed that in any
other world region. Well designed epidemiological
research can generate awareness, inform policy, and
encourage service development. However, such evidence
is lacking in many world regions, and patchy in others,
with few studies and widely varying estimates [19]. There
is a particular dearth of published epidemiological studies
in Latin America with two descriptive studies only, from
Brazil [21,22] and Colombia[23].
Developed/developing country differences
Prevalence of dementia is somewhat lower in developing
countries than in the developed north [2], strikingly so in
some studies [24,25]. Our expert consensus panel, review-
ing all available evidence, confirmed this trend [19],
which seems not to be explained by differences in sur-
vival[25,26]. Mild dementia may be under-detected
because of difficulties in establishing the criterion of
social impairment. Differences in levels of exposure to
environmental risk factors may also have contributed,
with low levels of cardiovascular risk [27] and hypolipi-
daemia [28,29] in some developing countries suggested as
explanations. Other potential risk exposures will be more
prevalent in LAMIC, for example anaemia associated with
AD in rural India [30]. Dietary deficiencies, particularly of
micronutrients, are widespread and strongly linked to
poverty. Deficiencies of folate and vitamin B12 are of par-
ticular interest given their consequences; anaemia, neu-
ropathy, hyperhomocysteinaemia [31], increased risk of
stroke and IHD [32]. Vitamin B12 deficiency is strikingly
prevalent (> 40%) across Latin America [33-35], linked to
gastrointestinal infections and diets deficient in meat and
dairy produce [33]. Folate deficiency is endemic in those
living in poverty [34], and after economic crisis [35]. Diets
deficient in legumes may have contributed. Micronutrient
deficiency is probably more prevalent in the elderly but
there are few data on this age group [33]. Iodine defi-
ciency has also been a major public health problem in
most Latin American countries [36]. Iodized salt is now
Demographic transition, UK and China Figure 2
Demographic transition, UK and China.
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generally available but iodine content is poorly regulated
[36]. We found only one study from the region, reporting
a prevalence of sub-clinical hypothyroidism of 16.1% in
post-menopausal Brazilian women [37]. High infant mor-
tality may contribute to population differences in demen-
tia frequency; constitutional and genetic factors that
confer survival advantage in early years may protect
against neurodegeneration or delay its clinical manifesta-
tions. According to this model, current dementia fre-
quency in developing countries would correlate inversely
with infant mortality at the time that those at risk were
born. In 1948, infant mortality in the UK was 38/1000
live births compared with 207 in Nigeria, 195 in China
and 190/1000 in India. Infant mortality in Latin America
varied from 40/1000 in Cuba, to 70 in Argentina, 81 in
the Dominican Republic, 98 in Venezuela, 102 in Mexico,
109 in Peru and 135/1000 in Brazil. [38]. It seems plausi-
ble that as patterns of morbidity and mortality converge
with those of the developed west, then dementia preva-
lence will do likewise [39].
Dementia aetiology
Dementia, cardiovascular risk factors and cardiovascular disease
Recent research suggests that vascular disease predisposes
to AD as well as to vascular dementia [40]. In short [41-
43] and longer latency [44,45] incidence studies, smoking
increases the risk for Alzheimer's disease. Inverse associa-
tions from case-control studies are thought to be
explained by prevalence-incidence bias, with smoking
influencing dementia-specific mortality [46]. Diabetes is
also a risk factor [47], and in longer term cohort studies,
midlife hypertension [48,49] and hypercholesterolemia
[49] are associated with AD onset in later life. Aggregated
cardiovascular risk indices incorporating hypertension,
diabetes, hypercholesterolaemia and smoking incremen-
tally increase risk for dementia incidence whether expo-
sure is measured in midlife [45] or a few years before
dementia onset [43]. Recent studies report associations
between metabolic syndrome and incident cognitive
decline [50], and insulin resistance and impaired execu-
tive function [51], but the role of the metabolic syndrome
is as yet little explored. Despite occasional negative find-
ings from large prospective studies [52,53], the accumu-
lated evidence for a causal role for CVRF and CVD in the
aetiology of dementia and AD is very strong. This has led
to the hypothesis that atherosclerosis and AD are conver-
gent disease processes [54], with some common patho-
physiological and aetiologic factors (APOE e4
polymorphism, hypercholesterolaemia, hypertension,
hyperhomocysteinaemia, diabetes, metabolic syndrome,
smoking, systemic inflammation, increased fat intake and
obesity).
Nutritional factors
Our review of the literature suggests two areas, of particu-
lar relevance to LAMICs, needing more research.
a) Research on micronutrients and dementia in developed
countries has focussed upon antioxidants [55] with less
attention towards deficiencies in vitamin B12 and folate,
which result in hyperhomocysteinaemia; only four small
incidence studies [56-59], all underpowered and with
inconsistent findings. Two out of three studies testing for
an effect of folate were positive [56,57], in one case inde-
pendent of homocysteine [56]. B12 was associated in only
one out of four studies [57].
b) Overt hypothyroidism is a potentially reversible cause
of dementia. Sub-clinical hypothyroidism (raised TSH
levels with normal T4) is more prevalent, affecting up to
20% of older people in developed countries. It is associ-
ated with elevated total cholesterol and progression to
overt hypothyroid disease, possibly also CVD [60]. It was
strongly associated with risk for dementia in one cross-
sectional study [61]. Conversely, a small incidence study
reported a strong association with sub-clinical hyperthy-
roidism (low TSH) [62].
Ethnic differences and research in admixed populations
Previous research indicates strong and consistent ethnic
differences in the incidence of dementia and stroke, in
shared risk factors for atherosclerosis and dementia (lipid
metabolism, hypertension, metabolic syndrome, APOE
genotype), and in risk associations between certain of
these risk factors and these outcomes.
Dementia
The age-specific prevalence [25] and incidence[26] of
dementia in Nigeria are both very low. A further notable
finding is the apparent lack of an association between
APOE genotype and dementia [63], confirmed in Kenya
[64]. Those with African ancestry tend to have a higher
prevalence of APOE e4, but African Americans, other pop-
ulations of west African ancestry, and Hispanics, all show
weak and inconsistent associations with AD [65]. There is
a robust association between APOE genotype and AD in
Europeans and south Asians [66].
Stroke, heart disease and CVD risk factors
In the South London Stroke study [67] age and sex
adjusted stroke incidence was higher among black (Afri-
can Caribbean) residents, with a RR of 2.2 (1.8–2.8). In
the USA incidence was higher among African Americans
and Hispanics [68,69]. These differences may be partly
explained by elevated blood pressure levels [70]. In the
North Manhattan Stroke Project, both relative risks and
population attributable fractions varied across white,
black and Hispanic ethnic groups for the major stroke riskBMC Public Health 2007, 7:165 http://www.biomedcentral.com/1471-2458/7/165
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factors [71]. Conversely, African Caribbean migrants in
the UK have a low risk of heart disease despite a high prev-
alence of metabolic syndrome, an effect attributed to a
low prevalence of smoking and low triglyceride levels
[70].
Admixture proportions
Measurement of individual admixture proportions (the
proportions of the individual's genome that are of Afri-
can, European, and Native American ancestry) is impor-
tant for three reasons.
1. Studying the relationship of disease risk to admixture
proportions is the most direct way to distinguish genetic
from environmental explanations for ethnic variation in
disease risk [72].
2. Such relationships will confound studies of any other
genetic or environmental risk factors – "hidden popula-
tion stratification". Measurement of the confounder
allows us to control for it by standard methods.
3. Genes underlying ethnic variation in disease risk may
be localized by admixture mapping, exploiting informa-
tion about linkage generated by admixture [73].
Aims of the 10/66 population-based research 
programme
Primary objectives
1. To create a publicly accessible data archive from the 10/
66 Dementia Research Group's cross-sectional popula-
tion-based surveys including over 17,000 older people
from six countries in Latin America and the Caribbean,
India, China and Nigeria.
2. To use these data for comparative descriptive analyses
of dementia prevalence, and its associated impact includ-
ing: the economic costs of illness in each centre compris-
ing indirect (informal care) costs, lost earnings and direct
costs (health and social care and medication); the relative
independent contribution of dementia and other major
non-communicable disorders to direct and indirect costs,
disability, dependency and caregiver strain.
3. To model dementia prevalence, examining the effects of
age, education, literacy and SES, and at population level of
urban vs. rural setting, historical levels of infant mortality,
economic development, and industrialization.
4. To conduct a 2.5 to three year incidence phase follow-
up of the baseline sample. The incidence phase will
exploit the particularly rich baseline cross-sectional data
in the six Latin American countries (Cuba, Dominican
Republic, Venezuela, Mexico, Peru and Argentina) and in
China, aiming:
5. To estimate the annual incidence rate of dementia and
its subtypes, by age group, education and centre, and to
investigate risk factors for incident dementia and AD, test-
ing the following specific hypotheses: a) cardiovascular
risk factors (diabetes, hypertension, large waist circumfer-
ence, high waist hip ratio, hypercholesterolaemia, hyper-
triglyceridaemia, metabolic syndrome and smoking) and
stroke increase the risk for incident dementia and AD,
after controlling for confounding effects. Associations will
be quantified as relative risks and population attributable
fractions; b) micronutrient deficiencies (vitamin B12 and
folate), and anaemia increase the risk for incident demen-
tia and AD, and mediate any effect on these outcomes of
overall nutritional deficiency; c) sub-clinical hypothy-
roidism is associated with increased risk of dementia and
AD; d) incident dementia and AD are inversely associated
with the proportion of the genome that is of African
ancestry, and the association between APOE e4 genotype
and incident dementia and AD is modified by admixture
proportions – weaker in those with least African ancestry.
6. To confirm the predictive validity of the survey demen-
tia diagnoses (DSM IV and 'the 10/66 dementia algo-
rithm') and Mild Cognitive Impairment (MCI) through
three year follow-up of all dementia and MCI cases. This
will include a longitudinal study of evolving care arrange-
ments and caregiver strain.
Secondary objectives
1. Mortality
a) to estimate annual all-cause and cause-specific mortal-
ity in each incidence centre; b) To investigate the inde-
pendent effects upon all-cause and cardiovascular
mortality of education, socio-economic status, cardiovas-
cular risk factors (CVRF), prevalent cardiovascular disease
(CVD), dementia, cognitive impairment, and depression
2. Stroke
a) to estimate, in the same centres the annual attack rates
for stroke; b) to compare the risk factor profile for incident
stroke (relative risks and population attributable risk frac-
tions) between centres and within centres between men
and women and better and less well educated partici-
pants.
3. Depression
To study the social aetiology of late-life depression cross-
sectionally in all ten centres, and prospectively in the inci-
dence centres including the effects of relative and absolute
poverty, ill health and disability, nutritional status, social
support, life events, marital circumstances and living
arrangements.BMC Public Health 2007, 7:165 http://www.biomedcentral.com/1471-2458/7/165
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Methods/design
The prevalence survey
Study design
Cross-sectional comprehensive one phase surveys have
been conducted of all residents aged 65 and over of geo-
graphically defined catchment areas in each centre with a
sample size of between 1000 and 3000 (generally 2000)
in each of the ten countries (see Table 1). Each of the stud-
ies uses the same core minimum data set with cross-cul-
turally validated assessments (dementia diagnosis and
subtypes, mental disorders, physical health, anthropome-
try, demographics, extensive non communicable disease
risk factor questionnaires, disability/functioning, health
service utilisation, care arrangements and caregiver
strain). The net result will be a unique resource of directly
comparable data, comprising 19,000 older adults from
three continents. DNA will be available from seven of the
ten countries. Fasting blood samples have been taken at
baseline from participants in seven countries – Brazil,
Cuba, Dominican Republic, Venezuela, Mexico, Peru and
Argentina, and analysed for full blood count and differen-
tial, glucose, cholesterol, triglyceride and albumin. Frozen
serum has been saved for further biochemical analyses.
Settings
Ten low and middle income countries (India, China,
Nigeria, Cuba, Dominican Republic, Brazil, Venezuela,
Mexico, Peru and Argentina). China, India, Peru and Mex-
ico recruited from separate urban and rural catchment
areas; the other centres included urban catchment areas
only.
Catchment areas and sample registration
For urban catchment areas predominantly middle-class or
professional areas with high-income earners were
avoided. Rural catchment areas were defined by low pop-
ulation density, and traditional agrarian lifestyle. Catch-
ment area boundaries were precisely defined. Mapping
was carried out to identify and locate all households,
which were allocated household IDs. Households were
enumerated to identify possible eligibles (aged 65 and
over). Age (and therefore eligibility) was formally deter-
mined on revisit for interview. For each household the
genders and ages of all usual residents was recorded with
the names of those aged 65 years or over on the census
date. Household and participant details were stored in
secure databases. These contained names, addresses, ID
numbers, and contact details for neighbours, key inform-
ants and friends to facilitate tracing for potential follow-
up. Precision calculations indicated that an overall sample
of 2,000 would allow estimation of a typical dementia
prevalence of 4.5% with a precision of +/- 0.9%. Rural and
urban samples of 1,000 each will allow estimation of the
same prevalence with a precision of +/- 1.2%.
Preparation
All centres had already been extensively trained in the
main diagnostic assessments (see below) for the purpose
of the dementia diagnostic pilot study [5]. Two further
one week project planning meetings were held, in London
for the PIs from Cuba, Brazil, DR, China and India and in
Caracas for the Venezuelan, Mexican, Peruvian and Argen-
tinean teams. One day follow-up meetings were held for
all PIs in Barcelona and Dominican Republic. A standard-
ized operating procedures manual covers every aspect of
the training and field procedures.
Interviews and measures
All assessments were carefully translated into the relevant
local languages (Ibero-American Spanish, Brazilian Portu-
Table 1: Overview of 10/66 population based surveys
Country (PI) Catchment area Target sample Interviews 
completed
Response % DNA Fasting blood 
sample
Start/finish
Cuba (Llibre) Havana (urban) 2100 2100 94% Yes Yes 6/03 12/05
Matanzas (urban) 900 900
Brazil (Menezes) Sao Paulo (urban) 2000 2000 93% Yes Yes 5/03 7/05
Dominican Rep. (Acosta) Santo Domingo (urban) 2000 2000 95% Blood (EDTA at -20 C) Yes 11/03 12/05
Venezuela (Salas) Caracas (urban) 2000 2026 79.6% Yes Yes 9/04 6/06
Mexico (Sosa) Mexico city (urban) 1000 1000 85.1% Blotting paper Yes 1/06 10/06
Morelos/Higalgo (rural) 1500 1000
Peru (Guerra) Lima (urban) 1500 1431 60% Blotting paper Yes 4/05 6/06
Canete (rural) 500 569
Argentina (Arizaga) Buenos Aires (urban) 1200 0 incomplete Yes Yes 4/05 6/06
Canuelas (rural) 800 800
China (Li/Huang) Xicheng (Beijing, urban) 1000 1000 83% No No 3/04 9/05
Daxin (rural) 1000 1001
India (Krishnamoorthy) Chennai (urban) 1000 1005 72% No No 2/04 12/05
India (KS Jacob) Vellore (rural) 1000 1000 98% No No 3/04 8/05
Nigeria (Richard Ukawa) Anambra (rural) 1000 500 incomplete No No
9 countries 13 catchment areas 20,000 17725BMC Public Health 2007, 7:165 http://www.biomedcentral.com/1471-2458/7/165
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guese, Tamil and Mandarin). Interviews were generally
carried out in participants' own homes. This was a com-
prehensive one phase survey – all participants receive the
full assessment, lasting approximately 2–3 hours.
1) Outcome – The diagnosis of dementia
Our previously published 10/66 dementia diagnosis algo-
rithm [5] requires
(i) A structured clinical mental state interview, the Geriat-
ric Mental State, which applies a computer algorithm
(AGECAT)[74], identifying organicity (probable demen-
tia), depression, anxiety and psychosis and,
(ii) A cognitive test battery comprising a) the Community
Screening Instrument for Dementia (CSI'D') COGSCORE
[75] (incorporating the CERAD animal naming verbal flu-
ency task), and b) the modified CERAD 10 word list learn-
ing task with delayed recall [76] and
(iii) An informant interview the CSI'D' RELSCORE [75],
for evidence of cognitive and functional decline
(iv) an extended informant interview, the History and
Aetiology Schedule – Dementia Diagnosis and Subtype
(HAS-DDS), a modification of the earlier HAS [77], pro-
viding more detailed information on onset and course of
a possible dementia syndrome
v) The NEUROEX, a brief fully structured neurological
assessment with objectified quantifiable measures of lat-
eralising signs, parkinsonism, ataxia, apraxia and primi-
tive 'release' reflexes [78,79].
(vi) Behavioural and Psychological symptoms of demen-
tia (BPSD); assessed using an informant questionnaire,
the Neuropsychiatric Inventory (NPI-Q) [80].
Final dementia diagnoses is made in two ways. The main
dementia outcome is defined as those scoring above a cut-
point of predicted probability of DSM IV Dementia syn-
drome [81] from the logistic regression equation
developed in the 10/66 international pilot study, using
coefficients from the GMS, CSI-D and 10 word list learn-
ing tasks [5]. The second approach involves the direct
application of research diagnostic criteria for DSM IV and
for the following dementia subtype diagnoses; NINCDS-
ADRDA Alzheimer's disease criteria [82], NINDS-AIREN
vascular dementia criteria [83], and Lewy Body Dementia
[84]. The clinical assessment identifies other prevalent
conditions relevant to the differential diagnosis of demen-
tia and dementia sub-type: psychosis, depression, anxiety
disorder, alcoholism, epilepsy and stroke. Circularity in
further validation of these diagnoses can only be avoided
by focusing upon their predictive validity. Thus, a diagno-
sis of dementia should lead to further cognitive and func-
tional decline, and not recovery.
2) Blood sample protocol
Fasting blood samples were sought from all participants
in all centres other than India, China and Nigeria, neces-
sitating revisits for phlebotomy first thing in the morning.
15 mls of blood was drawn and distributed as follows;
one 5 ml plastic EDTA for haematology and DNA extrac-
tion or storage, one 2.5–3 ml Fluoride Oxalate bottle for
glucose and the remainder (approx 8 ml) to a clot bottle
for biochemistry. Samples were transferred immediately
to the laboratory for haematological and biochemical
analysis (see below). Serum obtained from centrifuging
the clot sample was divided into aliquots and fresh frozen
at -20 C. For the DNA collection, in Cuba and Venezuela
the EDTA samples are processed and DNA extracted
immediately. In Dominican Republic the EDTA sample is
frozen at -20 C. In Peru, Argentina and Mexico blood is
collected onto FTA Elute (Isocode) cards. Each 3 mm
punch yields 20 × 50 ul PCR reactions (100 × 10 ul) so
one card set generates 640 × 50 ul PCR reactions.
3) Genotyping
DNA will be extracted and stored from all seven centres.
APOE genotyping will be conducted on all samples, and
60 SNPs informative for African/European ancestry
admixture will be genotyped from centres where admix-
ture is relevant (Cuba, Dominican Republic, Mexico, Peru
and Venezuela). The 60 SNPs will be chosen from the
panel assembled by Dr Mark Shriver at Penn State and
Mike Smith at NCI [85]. With 60 SNPs that have average
40% information content for ancestry, we shall be able to
estimate three-way individual admixture proportions
with a standard error of less than 0.1.
4) Principal exposures – environmental
This information was elicited from participants; with
informants also interviewed for those with communica-
tion difficulties arising from dementia, severe mental ill-
ness, deafness or mutism.
4.1 Sociodemographic status
a) age, living circumstances (complete list of coresidents
with ages and relationships), marital status, education, lit-
eracy, religion affiliation and practice, community social
activity, social support, social network
b) Socio-economic status – best occupation (self and
spouse), current occupational status, income and sources
of income, household assets index, food insecurity
c) Migration status – Rural or urban residence across the
life course. Age when moved,BMC Public Health 2007, 7:165 http://www.biomedcentral.com/1471-2458/7/165
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4.2 Health status
a) self reported global health,
b) self-reported diagnoses (stroke, diabetes, hypertension,
heart disease, hypercholesterolaemia, TB, malaria, and
cystercicosis) and treatments for these conditions
c) a self-reported list of 12 commonly occurring physical
impairments [86];
d) activity limitation and participation restriction meas-
ured by the WHO-DAS II [87], specifically developed by
the WHO as a culture-fair assessment tool for use in cross-
cultural comparative epidemiological and health services
research.
e) direct physical assessments – pulse rate, systolic and
diastolic resting blood pressure (average of two, sitting
and standing), waist circumference, waist/hip ratio, walk-
ing test (5 metres walk, turn and return – timed and paces
counted).
f) Reproductive status (for women) – menarche, meno-
pause, reproductive period, number of children
4.3 Biological assessments
a) Physical assessments – pulse rate, systolic and diastolic
resting blood pressure (average of two, sitting and stand-
ing), waist circumference, waist/hip ratio, leg length,
height, skull circumference, walking test (5 metres walk,
turn and return – timed and paces counted).
b) Haematological tests; full blood count (haemoglobin,
haematocrit, differential, MCV, MCH, MCHC).
c) Biochemical tests; fasting glucose, fasting total choles-
terol and sub-fractions, triglyceride, albumin, total pro-
tein.
These data collected allow us to identify metabolic syn-
drome according to the criteria proposed by the Third
Report of the National Cholesterol Education Program
(NCEP – ATP III) : presence of three or more of the follow-
ing; 1. Central obesity as measured by waist circumfer-
ence: Men > 40 inches, Women > 35 inches. 2. Fasting
triglycerides >= 150 mg/dL. 3. HDL cholesterol: Men < 40
mg/dL, Women< 50 mg/dL. 4. Blood pressure >= 130/85
mmHg. 5. Fasting glucose >= 110 mg/dL
4.4 Risk exposures
a) specific dementia risk factors – head injury with loss of
consciousness, family history of dementia, previous
depression, leg length, height, skull circumference,
b) Lifestyle and cardiovascular risk factors – alcohol use
(volume and frequency currently and before the age of
60), lifetime smoking (never, ever and current smokers
and pack year calculation), diet (intake of fish, meat and
fruit and vegetables; food insecurity), exercise and activity
levels now and in earlier life.
5) Measures of care arrangements, and impact of providing care on 
caregivers
These measures have been refined and validated in the 10/
66 group's pilot studies[9,12].
a) Economic impact was assessed using the Client Service
Receipt Inventory [88], a comprehensive assessment of
direct and indirect economic costs for mental health serv-
ices, adapted for use in the developing world. It elicits
information on type and cost of accommodation, income
(from all sources) for the person with dementia and the
principal caregiver, the occupation of the caregiver, the
extent to which the caregiver had cut back on or stopped
work in order to provide care, unpaid care provided by
family or others in the community, paid care inputs and
their costs, and the use (and associated costs) of a variety
of health care services; hospital services (inpatient and
outpatient); government community health services (gen-
eral practitioner, nurse, community health worker, other
health worker); private doctor; dentist; time and duration
of visits, out of pocket costs for the consultations and
medications, time taken to travel, cost of travel.
b) Practical impact – contact time between caregiver and
cared for person [89], whether or not care was being pro-
vided. Time spent by the caregiver in the last 24 hours in
specific caregiving activities [90]; communicating, using
transport, dressing, eating, looking after one's appearance,
and supervising,
c) Caregiver perceived strain – the Zarit Burden Interview
(ZBI) [91-93] with 22 items that assess the caregiver's
appraisal of the impact their involvement has had on their
lives.
d) Caregiver mental health (the Self Reporting Question-
naire 20) [94].
e) Behavioural and Psychological symptoms of dementia;
the Neuropsychiatric Inventory (NPI-Q)[80]
Resources/training/quality control
Each centre had a project coordinator and 4–10 interview-
ers. These were generally lay graduates, although Cuba
and China used medical doctors. All researchers were rig-
orously trained in a) study protocol and procedures, b)
standard structured interviewing techniques, c) a specific
two day training for the Geriatric Mental State structuredBMC Public Health 2007, 7:165 http://www.biomedcentral.com/1471-2458/7/165
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clinical mental status assessment and the neurological/
physical examination. MP had trained the project PIs and
video training materials were provided for local centres.
Field interviews were regularly checked and supervised.
Data management
In Cuba, all data was collected directly onto laptop com-
puters using computerized Spanish questionnaires driven
by EpiData (version 2.0) software. These questionnaires,
developed by the 10/66 group incorporate conditional
skips, and interactive checking of data consistency. In
other Hispanic centres, data was collected onto paper and
double data entered onto the same EpiData files. Chinese
and Indian centres used English language data entry files.
Identical EpiData files in all centres facilitates data
processing, data merging and archiving. Data is extracted
into SPSS, and all processing (cleaning, processing of
derived variables and running of 10/66, DSMIV dementia
and other diagnostic algorithms) is carried out using SPSS
batch files. The end result is a cleaned, processed and
labelled data set that can be exported into other statistical
programs for further analysis.
Ethical issues
Participants were recruited following informed signed
consent. Persons with dementia who lack capacity for
consent were recruited on the basis of a relative's signed
agreement. Illiterate persons were read the information
sheet and consent form, and invited to express their con-
sent verbally, which was witnessed. Participants were
invited to make a gift of genetic material (blood) to the
local research institutions who act as custodians in whom
are vested full rights for scientific and commercial exploi-
tation, subject only to limitations upon the phenotypes to
be investigated. Studies were approved by local ethical
committees as well as by the ethical committee of the
Institute of Psychiatry, King's college London.
Incidence phase
Tracing participants
Response rates for the baseline surveys were generally
high, ranging from 74 to 98% (see Table 1). For the fol-
low-up, which was pre-planned at baseline, we have col-
lected the names, addresses and telephone numbers of
three non co-resident local relatives, friends or neighbours
who can be contacted to help trace the participant if they
are not at their original address. The population in each of
the settings where we are working is stable. Apart from a
likely 6% per annum attrition from mortality, we antici-
pate a very high follow-up rate, in excess of that typically
achieved in cohort studies in developed countries. All
methods, procedures and logistics are well established
from the 10/66 baseline surveys.
Protocol
The interviews for the incidence phase largely involve a
repeat of the one phase dementia diagnostic protocol pre-
viously described, with the aim of identifying incident
dementia. We will modify the DSMIV algorithm to incor-
porate cognitive test and informant data from baseline
into the direct determination of cognitive and functional
decline. We will also reassess risk exposures that may have
changed over the three years since baseline. All partici-
pants will receive the same comprehensive assessment,
very similar to that administered in the baseline survey,
regardless of their baseline status. Those with dementia at
baseline will have been at risk for stroke, and we will
repeat dementia assessments to assess course and out-
come and to validate baseline diagnoses. We will also
review care arrangements, dependency and indices of car-
egiver strain. Interviewers will be blinded to baseline diag-
nostic status.
Interviews and data collection
Mortality
For those who died between baseline and follow-up
(information ascertained on follow-up visit) we will com-
plete a verbal autopsy interview with a co-resident, rela-
tive or other person well-placed to know the
circumstances of death, using methods developed and
validated by the 'Million Deaths' project for use in India
[95,96] to identify underlying cause according to ICD10
criteria. The interview takes 30–45 minutes using struc-
tured questions and an open-ended narrative, with a
symptom list to assist attribution. Cause of death is allo-
cated by the consensus judgement of two physicians. The
approach is valid for use up to three years post-mortem.
We will also attempt to ascertain whether the participant
had an onset of dementia before death, using the standard
10/66 informant assessment.
Stroke
We also include a two phase clinical protocol designed to
identify incident stroke. All those claiming (by participant
or informant report) to have experienced a stroke in the
interval between assessments, and all those with sugges-
tive neurological signs (asymmetric long tract signs, dys-
phasia, marked gait disturbance) not apparent at baseline
will be offered physician assessment including physical
examination, clinical history, and examination of clinical
notes and investigations where available ('cold pursuit').
We will then seek consensus diagnosis from two local
independent experts. Stroke diagnosis (ARIC criteria [97])
require
a) evidence of sudden or rapid onset of neurological
symptoms
b) lasting for more than 24 hours or leading to death,BMC Public Health 2007, 7:165 http://www.biomedcentral.com/1471-2458/7/165
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c) in the absence of evidence for a nonstroke cause (brain
trauma, neoplasm, coma attributable to metabolic disor-
ders or disorders of fluid or electrolyte balance, CNS vas-
culitis or infection, and peripheral neuropathy).
In our baseline data set 96% of those who reported a
stroke had a clinical diagnosis, 81% from a specialist.
However, neuroimaging will not routinely be available,
and we cannot be confident that we will have enough
information to attribute stroke sub-type with confidence.
Silent brain infarctions (picked up by neuroimaging with-
out clinical symptoms and signs) will not be included.
New retrospective exposure data (not collected at baseline)
Number of remaining teeth, use and quality of dentures
Use of lipid-lowering agents
Calf circumference
Weight (using digital scales)
Grip strength
Interviewer assessment of mobility (bedbound/chair-
bound/housebound/limited mobility outside/unre-
stricted mobility
New biochemical assays
Fresh frozen serum from baseline collections are available
in Cuba, DR, Venezuela, Peru, Argentina and Mexico. We
will use these to investigate associations between micro-
nutrient deficiency and dementia/AD. We will use a
nested incident case control design whereby for each inci-
dent case, we shall select three controls at random from
among those matching for age, gender and education,
who were free of dementia at the time of onset for the
case. Assuming 219 incident cases in these six centres (see
below) this will imply 876 samples to be assayed for Vita-
min B12, folate, TSH and T4. Routine assays will be car-
ried out by local laboratories, but procedures will be
standardised as far as possible. Fresh frozen serum stored
at -20 C is appropriate for these analyses.
Analyses
Description of incidence
Person-years at risk will be calculated as the interval
between baseline and follow-up assessment, or the esti-
mated time of onset of dementia, or the time of death,
whichever occurs sooner. Age-specific incidence (with
Poisson standard errors and 95% confidence intervals)
will be estimated for each country, by gender and age in 5-
year bands by dividing number of cases by number of per-
son-years contributed in each age band. Dementia onset is
assumed to be the midpoint between the last date when
known to be dementia free and the first date of dementia
diagnosis (either by survey ascertainment or clinical infor-
mation). A similar procedure will be used to calculate
stroke attack rates.
Hypothesis testing
We will use Cox's proportional hazards regression
throughout to estimate risk associations. Informative cen-
soring may occur through the competing risks of partici-
pants dying and becoming lost to follow-up in the interval
between assessments. This problem is only rarely
addressed in dementia cohort studies [53]. We will do so
firstly by verbal autopsy interviews with key informants
for all deceased persons, and secondly (in a sensitivity
analysis) by using proportional subdistribution hazards
regression [98] to account for informative censoring
through explicit analysis of competing risks.
The ADMIXMAP program [99] will be used to model
genetic admixture. In two-step analysis, estimates of indi-
vidual admixture generated by ADMIXMAP are simply
plugged into standard programs for statistical analysis.
One-step analysis fits regression models for the effect of
individual admixture and other risk factors (genetic or
environmental) on disease risk. This allows for the uncer-
tainty in estimation of individual admixture from the
marker data, eliminating residual confounding by popu-
lation stratification that may occur in a two-stage analysis
using a small number of markers, and allows us to model
haplotypes given unphased genotype data. For this study,
ADMIXMAP will be extended to support Cox regression
(regression algorithms are based on a GLM approach). We
shall test for
1) effects of individual admixture on dementia, AD and
other outcomes
2) effects of individual admixture on the slope of relation-
ship of APOE to dementia.
3) effects of other environmental factors or genetic poly-
morphisms on dementia, again controlling for popula-
tion stratification.
Power and sample size considerations
Power estimations were carried out using Stata 8.2
ssmenu command [100] for sample size and power calcu-
lations in complex studies with failure time outcomes
(table 2). Pooling the data across the six Latin American
centres yields the following power (Table 3) for identifica-
tion of the following effect sizes for associations with inci-
dent dementia and stroke, assuming the following
prevalences of risk exposure.BMC Public Health 2007, 7:165 http://www.biomedcentral.com/1471-2458/7/165
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For the nested incident case-control study we estimate
that 219 cases and 657 matched controls will be available.
Given the matching, all analyses will be carried out using
conditional logistic regression (Stata 8.2). For exposure
prevalences ranging from 5% (lowest realistic estimate of
prevalence for folate deficiency and subclinical hypothy-
roidism) to 40% (likely prevalence of vitamin B12 defi-
ciency) such a comparison will have good (80%) to
excellent (90%) power for detecting policy-relevant effects
(Table 4).
The casefinder study
After one day of training on the clinical characteristics,
presentation and course of dementia, community key
informants will generate, from their knowledge of the
local population names of those living in the catchment
areas to be surveyed, who they think may be possibly or
probably suffering from dementia. Key informants may
be community health workers, social welfare officers,
community activists or other volunteers depending upon
the local health system. The aim is to identify where pos-
sible the cadre of workers with a community outreach role
and some consequent knowledge of the circumstances of
all or many of the local inhabitants. These assessments
will then be validated against the comprehensive struc-
tured clinical diagnostic assessment from the subsequent
cross-sectional survey. The sensitivity, false positive rate,
and positive and negative predictive values of the demen-
tia case-finding procedure will be estimated with respect
to the criterion of the structured clinical research diagno-
sis. The characteristics of those with research dementia
diagnoses who were and were not nominated by commu-
nity key informants will be compared to identify factors
predicting failure of detection. Factors to be assessed
include age, gender, marital status, living circumstances,
socio-economic status, rural or urban residence, recent
use of health services, severity of dementia, subtype of
dementia, co-morbidity, associated behavioural prob-
lems, time spent caregiving, caregiver strain and mental
health status. A sample of 2,000 in each centre will pro-
vide approximately 90 cases of dementia allowing sensi-
tivity to be estimated with a precision of +/- 7%, and a
Table 3: Power to detect given effect sizes (HRs) for associations between exposures with a prevalence of 10% and 20%, for the 
outcomes of dementia and stroke.
Minimum Hazard Ratio to be 
detected
Power for detecting association with 10% exposure 
prevalence
Power for detecting an association with 20% exposure 
prevalence
Outcome1,2 Dementia Stroke Dementia Stroke
2.5 100% 99.8% 100% 100%
2.0 96.4% 90.9% 99.8% 98.8%
1.8 86.0% 75.8% 97.5% 92.8%
1.5 48.8% 39.3% 71.0% 59.5%
1. The power to detect associations with all-cause mortality approximates to 100% in each of these cells
2. As approximately 70% of dementia cases are categorised as AD, the power of detecting given associations with this outcome is very similar to 
that for stroke.
Table 2: Incident dementia, stroke and all-cause mortality in centres participating in the follow-up study
Country Baseline sample Dementia 
at baseline
Free of dementia 
at baseline
Available for FU 
interview1
Person years Deaths Incident 
dementia2
Incident 
strokes
Cuba 3000 330 2670 1994 6730 509 55 45
DR 2000 220 1780 1329 4488 339 37 30
Venezuela 2000 200 1800 1345 4490 339 37 30
Mexico 2000 200 1800 1381 2906 295 30 25
Peru 2000 200 1800 1381 2906 295 30 25
Argentina 2000 200 1800 1381 2906 295 30 25
Sub-total3 13000 1350 11650 8811 24426 2072 219 180
China 2162 137 2025 1513 5105 366 42 30
TOTAL 15000 1300 11700 10324 29531 2438 261 210
1. assuming 6% annual mortality (GBD 2002 AMRO B mortality data, 65 and over), and 15% non-response/non-traceability.
2. annual incidence rate of 0.0092 for all those aged 65 and over, from consensus prevalence estimates for Latin America [19], using DISMOD to 
derive incidence from prevalence and survival.
3. These centres included fasting blood samples, which are lacking in ChinaBMC Public Health 2007, 7:165 http://www.biomedcentral.com/1471-2458/7/165
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difference in sensitivity between (for example) rural and
urban areas of 30% (80% vs 50%) to be detected with
95% confidence and 80% power.
The 10/66 caregiver education and training intervention
The 10/66 intervention was developed in India (for use by
multi-purpose health workers), but with input from the
wider 10/66 group including developed country experts.
It targets the main carer, but includes members of the
extended family. The aim is to provide basic education
about dementia and specific training on managing prob-
lem behaviours. The three simple, manualised modules
are delivered over five, weekly, half hour sessions.
Module 1. Assessment – 1 session
a) Cognitive/functional impairment b) Carer's knowledge
and understanding of dementia. c) Care arrangements
(Who are the family members? Who lives with the person
with dementia? How do they assist the main carer? Which
behavioural problems present most difficulties? How bur-
dened do they feel?).
Module 2. Basic education – 2 sessions
a) general introduction to the illness. b) what to expect in
the future c) What causes/does not cause dementia? d)
locally available care and treatment.
Module 3. Training on problem behaviours – 2 sessions
Problem behaviours identified in the assessment are
addressed (personal hygiene, dressing, incontinence,
repeated questioning, clinging, aggression, wandering,
apathy). After extensive piloting the intervention is now
supported by a structured, manualised two day training
program for MPHWs comprising a) basic knowledge
about dementia, b) assessment skills, c) basic counselling
skills and d) role playing of intervention scenarios.
In Argentina, Mexico, Peru, Venezuela, Russia, and China,
we are carrying out a formal randomised controlled trial;
all people with dementia identified in the population-
based survey (and their carers) will be offered randomisa-
tion to receive the caregiver training and education inter-
vention either a) immediately or b) after 6 months, that is
after the final outcome assessments will already have been
completed. The inclusion criterion is a 10/66 algorithm
diagnosis of dementia. Exclusion criteria are serious inter-
current illness in the person with dementia, or absence of
family caregivers. Consent is obtained from the person
with dementia, where possible, and their principal car-
egiver. The principal caregiver is the family member or
close friend who is most involved in providing and/or
organising care for the person with dementia. Paid car-
egivers and/or other family caregivers may participate in
the intervention but are not subject to the outcome assess-
ment. In the pre-randomisation visit, a research worker
completes the baseline assessments (see below), explains
the trial and seeks informed consent from the person with
dementia and the caregiver. Randomisation is carried out
in London, and the codes transmitted to the local 10/66
centre by fax or e-mail. Randomisation is by permuted
block to ensure in each centre an even distribution of
baseline caregiver strain. The intervention in all centres
will be evaluated in terms of uptake rates, completion
rates and satisfaction rates (among caregivers), together
with before (baseline) and after (six months) intention to
treat comparisons of standard assessments. Principal out-
comes related to the caregiver are caregiver role strain
(Zarit caregiver burden interview), psychological distress
(SRQ 20), and quality of Life (the 17 item WHO-QoL
Bref) [101]. Principal outcomes related to the person with
dementia are behavioural and psychological symptoms of
dementia (Neuropsychiatric Inventory – NPI-Q) [80] and
quality of life (DEMQoL) [102].
The clinician (if any) responsible for clinical care of the
person with dementia will be blind to the intervention.
They may organise any supplementary care that they feel
is indicated. The assessor, assessing outcome after the
intervention will be blind to the intervention. The family,
and the assessor will be asked to do everything they can to
maintain blindness. Primary endpoint analysis will be
according to intention to treat with last observation car-
ried forward for missing data. Failures of randomization
would be adjusted for as factors or covariates, using gen-
eralized linear modelling. In each centre, with 30 families
randomised to the control and intervention arms, the
study is powered to detect moderate effect sizes (0.8 or
greater for change scores on continuously distributed out-
comes) associated with the intervention, at 80% power
and 95% confidence. Data from the different centres
would be subject to meta-analysis. (ISRCTN41039907;
ISRCTN41062011; ISRCTN95135433;
ISRCTN66355402; ISRCTN93378627;
ISRCTN94921815).
Discussion
The contribution of the 10/66 studies
Despite some excellent studies, dementia in LAMIC
remains under-researched, particularly given its large,
growing public health and societal impact. There are ineq-
uities in the increasing attention directed towards NCDs
in LAMIC. Relatively little research, policy or practice is
directed towards older adults. Premature mortality is
given more attention than living with disability. Accord-
ing to the 2003 World Health Report Global Burden of
Disease estimates, dementia contributed 11.2% of all
years lived with disability among people aged 60 and
over; more than stroke (9.5%), musculoskeletal disorders
(8.9%), cardiovascular disease (5.0%) and all forms of
cancer (2.4%). Our programme of population-based stud-BMC Public Health 2007, 7:165 http://www.biomedcentral.com/1471-2458/7/165
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ies in ten developing countries provides a powerful
resource for comparative descriptive research of preva-
lence, incidence, impact and cost. The main aim of the
incidence phase is to investigate aetiology (a particularly
neglected area). Findings from the west (for example, car-
diovascular risk factors as risk factors for dementia) may,
or may not generalise. Both exposure prevalence and
effect sizes may differ between regions because of popula-
tion-specific genetics, culture (behaviour and lifestyles)
and physical environment. Other exposures, for example
micronutrient deficiency, are rare in richer countries but
highly prevalent and potentially of great significance in
Latin America and China. Population attributable frac-
tions will assist in determining priorities for future health
promotion and primary care prevention in these regions.
While cardiovascular disease and its risk factors are also
relatively little studied in Latin America, two new initia-
tives will soon contribute relevant data[103]; the PRE-
VENCION study in Arequipa, Peru involves a
comprehensive assessment of cardiovascular risk factors
and outcomes among 1600 community residents aged
20–80, while the CARMELA study will provide similar
data in younger samples (aged 25–64) from seven coun-
tries – Colombia, Argentina, Peru, Mexico, Ecuador, Chile
and Venezuela. Our 10/66 population-based studies will
neatly complement the CARMELA database by providing
information from many of the same countries on those
aged 65 and over.
Methodological issues
Our one phase dementia diagnostic assessment has
advantages over the two phase approach used in most pre-
vious dementia cohort studies [104]. Attrition is marked
between the first and second phase [2]; participants with
probable dementia are particularly likely to refuse, to
move away or to die, leading to informative censoring.
The problem is compounded when no random sample of
screen negatives is selected for second phase assessment
with the tacit assumption of perfect sensitivity for the
screening measure [104-106].
The 10/66 dementia diagnosis has been carefully vali-
dated across all of the cultures, and in each of the centres
in which the population research is proceeding. While
sensitivity (94%) and specificity (97% in high education
controls and 94% in low education controls), against the
gold standard of a local clinician's DSM IV diagnosis were
both excellent, the false positive rate which varied
between 1% and 10% across regions and levels of educa-
tion can be expected to result in a higher prevalence of 10/
66 dementia, compared with that of DSM IV dementia.
DSMIV criteria are recognized to be relatively restrictive.
Impairment is required in memory and other specified
domains of function. Each of these must have progressed,
and led to social or occupational impairment. The deficits
should not be explained by delirium or other mental dis-
order. The aim with DSMIV (and other similar diagnostic
criteria) was to define a progressive and relatively perva-
sive disorder with thresholds set high to maximize relia-
bility between raters and centres. Clinically relevant
dementia may therefore be prevalent beyond the confines
of the narrowly defined DSM IV criterion. One of the few
population-based studies to examine this issue directly,
the Canadian Study of Health and Aging [107] reported a
prevalence of 20.9% for those aged 65 and over according
to clinical consensus compared with 13.7% according to
DSM IV criterion. Mild cases, confirmed by clinicians,
were selectively excluded by the DSM IV criterion. None of
the DSM IV criteria are specifically required by the 10/66
probabilistic algorithm, which simply requires a profile of
cognitive impairment on formal testing, informant
reports of cognitive and functional decline, and findings
on clinical interview that are consistent with a high prob-
ability of being a case. While the DSMIV algorithm identi-
fies clear cut, severe and pervasive dementia cases, the 10/
66 algorithm may be more relevant to establishing the
true population burden of the dementia syndrome.
The catchment area sampling strategy enables us to foster
links within each local community, improving response
and facilitating possible follow-up. Community sensitisa-
tion proved to be essential to ensure a good response to
the surveys. Prevalence estimates and other descriptive
elements may not generalize beyond these and similar
communities, but this is unlikely to lead to bias in esti-
mates of association.
Dissemination
An action research program of this kind stands or falls
upon its ability to inform and encourage policy develop-
ment on the basis of the evidence accumulated through its
activities. The 10/66 Group recently held a one week
workshop at the Rockefeller Center in Bellagio to address
the need to exploit fully the potential created by the 10/66
population based and intervention studies. Dissemina-
tion through a peer reviewed scientific journal is but one
important element of this process. Our challenge is to use
our findings to raise public awareness, stimulate local
clinical training and practice, and influence social welfare
and health care policy making at the national and interna-
tional level. In these respects, our relationship with ADI
(Alzheimer Disease International) is crucial. ADI is affili-
Table 4: Minimum detectable effect size (OR) for matched 
incident case-control comparison
Exposure Prevalence Power 5% 10% 15% 40%
80% 2.4 2.0 1.8 1.6
90% 2.7 2.2 2.0 1.7BMC Public Health 2007, 7:165 http://www.biomedcentral.com/1471-2458/7/165
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ated to the World Heath Organisation. The needs of peo-
ple with dementia in developing countries is now a major
priority for ADI, and our findings are disseminated on its
website [3], at its conferences, and in its regular newslet-
ters and World Alzheimer's Day Bulletins, distributed to
its 76 member associations worldwide. In turn, the
national Alzheimer's associations are able to use our
materials for local publicity, and to influence national
policy makers as part of their lobbying activities at govern-
ment level. Other committed NGOs may have a key advo-
cacy role to play, and we will need to work intersectorally
to maximise dissemination and policy impact. Dementia
is one of many health conditions in the developing world
characterised by lack of awareness, stigma, limited help
seeking, few services, and much unmet need. The evidence
provided by research, disseminated actively by committed
NGOs can be a powerful argument for change.
At the Bellagio meeting we devised a strategy for dissemi-
nation focusing upon: Identifying key stakeholders;
designing and conducting local workshops; forging links
with policymakers, understanding their preoccupations,
and preparing policy briefings in each of the countries/
regions where we are working; linking with the print and
radio news media in developing countries, and under-
standing how its support may be elicited in raising aware-
ness; exploiting links between 10/66 researchers and
national Alzheimer's Associations; forming intersectoral
links with other relevant NGOs e.g HelpAge International,
Save the Children (cross-generational effects), Oxfam
(economic impact of aged care, and poverty reduction)
All investigators in this programme are committed to
establish a monitored public access fully anonymised file
sharing archive, to maximize exploitation of the data
resource. The Brazilian centre is making its own local
arrangements. For all other centres, data will be forwarded
to the coordinating centre for further cleaning and check-
ing for compatibility with the uniform file format. The
final version will be approved by the local centre, archived
in a secure directory on the Institute of Psychiatry net-
work, and shared with all centres participating in the
archive. Proposals for multi-centre publications may be
made by the coordinator, by centre PIs, or by external
investigators. Access will not unreasonably be denied, and
will be approved by a publications committee with two
members from each centre. The 10/66 programme steer-
ing committee will give independent oversight. In the
interests of transparency, all interviews, data entry files,
algorithms, protocols, training materials and manuals can
be downloaded from our intranet site[108]. Applications
for use of the data should be sent to
1066drg@iop.kcl.ac.uk.
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